Hawaii · 2026 Regular Session
Establishes the Prescription Drug Affordability Board within the Department of Health to conduct affordability reviews on high-cost prescription drugs and establish upper payment limits under certain circumstances. Establishes out-of-pocket maximums for prescribed insulin, asthma inhalers, and epinephrine auto-injectors. Prohibits copayment adjustment programs. Requires health insurers, mutual benefit societies, and health maintenance organizations to comply with certain affordability measures. Requires annual reports to the Legislature. Requires adoption of rules by the Affordability Board and Insurance Commissioner. Appropriates funds.
The committee on CPN deferred the measure. (2026-02-18)